In healthy participants, cagrilintide 4.5 mg did not cause clinically relevant QTcF prolongation versus placebo; the upper 90% CI limits were below 10 ms at all time points.
In plain wordsIn healthy people, cagrilintide did not lengthen the heart QT interval in a relevant way compared with placebo.
- Peptide
- Cagrilintide
- Outcome
- No significant changePlacebo-adjusted QTcF change from baseline
- Study
n = 105
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Heart function · Cardiovascular
- Studied dose
- 4.5 mg once weekly (dose escalated) · subcutaneousAs given in this study (human).
Measurements
- Upper limit of two-sided 90% CI of placebo-adjusted QTcF change
- < 10 ms
- all four time points
Source sentences
No clinically relevant QTcF prolongation occurred after the last cagrilintide 4.5-mg dose; the upper limits of the two-sided 90% CIs of the placebo-adjusted QTcF changes from baseline were below 10 ms at all time points.
2 context sentences(design, population, supporting numbers)
This was a double-blind study (NCT05804162) in which healthy participants were randomized to cagrilintide, administered as a once-weekly subcutaneous injection dose escalated to 4.5 mg, or a placebo.
A total of 105 participants received cagrilintide (n = 53) or placebo (n = 52).